Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 August 2020Website:
http://orchestrabiomed.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 30 Sep 2024 20:00:11 GMTDividend
Analysts recommendations
Institutional Ownership
OBIO Latest News
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.35 per share a year ago.
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.
Orchestra BioMed Holdings, Inc. (OBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Orchestra BioMed Holdings, Inc. (OBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Orchestra BioMed Holdings, Inc. (OBIO) reported a quarterly loss of $0.38 per share, slightly better than the expected loss of $0.40 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.40 per share reported in the same quarter last year.
Orchestra BioMed (OBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout November and Deccember.
Orchestra specializes in developing medical devices, then pairing with established companies to market those devices. The company went public via a SPAC merger early this year.
What type of business is Orchestra BioMed Holdings?
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
What sector is Orchestra BioMed Holdings in?
Orchestra BioMed Holdings is in the Healthcare sector
What industry is Orchestra BioMed Holdings in?
Orchestra BioMed Holdings is in the Biotechnology industry
What country is Orchestra BioMed Holdings from?
Orchestra BioMed Holdings is headquartered in United States
When did Orchestra BioMed Holdings go public?
Orchestra BioMed Holdings initial public offering (IPO) was on 04 August 2020
What is Orchestra BioMed Holdings website?
https://orchestrabiomed.com
Is Orchestra BioMed Holdings in the S&P 500?
No, Orchestra BioMed Holdings is not included in the S&P 500 index
Is Orchestra BioMed Holdings in the NASDAQ 100?
No, Orchestra BioMed Holdings is not included in the NASDAQ 100 index
Is Orchestra BioMed Holdings in the Dow Jones?
No, Orchestra BioMed Holdings is not included in the Dow Jones index
When was Orchestra BioMed Holdings the previous earnings report?
No data
When does Orchestra BioMed Holdings earnings report?
The next expected earnings date for Orchestra BioMed Holdings is 13 November 2024